We are pleased to have the opportunity of this rejoinder, which permits a broader discussion on the issues surrounding proprietary models than in our article, "The age of secrecy and unfairness in recidivism prediction." We would like to thank all discussants, and the Editor for organizing the discussion. We will start our discussion with the response to Eugenie Jackson and Christina Mendoza, who represent Northpointe, the company that owns COMPAS.
No takes yet. Share an insight, caveat, or question.
Rudin et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: